AstraZeneca puts leading COVID-19 vaccine trial on hold over safety concern

Reuters 09/09/2020

AstraZeneca Plc on Tuesday said it has paused a late-stage trial of one of the leading COVID-19 vaccine candidates after an unexplained illness in a study participant. “Our standard review process was triggered and we voluntarily paused…

PH won’t get COVID-19 vaccine from China, Russia for free – Duterte

Darryl John Esguerra 08/18/2020

MANILA, Philippines — The vaccine against the coronavirus disease 2019 (COVID-19) developed in China and Russia will not come in the Philippines for free, President Rodrigo Duterte said Monday night, adding that the government would borrow funds,…

Russia produces first batch of COVID-19 vaccine—report

Reuters 08/16/2020

MOSCOW—Russia has produced the first batch of its new vaccine for COVID-19, the Interfax news agency quoted the health ministry as saying on Saturday, hours after the ministry reported the start of manufacturing. Some scientists said they…

FDA assures no shortcuts in approval of COVID-19 vaccine

Daphne Galvez 08/14/2020

MANILA, Philippines — The Food and Drug Administration (FDA) will not approve a COVID-19 vaccine unless it has completed all the required  local procedures to ensure its safety and efficacy. FDA Director General Eric Domingo made the…

Abellanosa’s bill seeks to give every Filipino access to free COVID vaccine when ready

Delta Dyrecka Letigio 08/07/2020

CEBU CITY, Philippines — Rep. Rodrigo Abellanosa of Cebu City’s south district has filed a bill in Congress that will make sure that every Filipino citizen will have access to free coronavirus disease vaccine as soon as…

Vaccine being developed at Oxford to be available at cost price

07/23/2020

  PARIS — A coronavirus vaccine being developed by the University of Oxford and AstraZeneca should be available globally “at cost price” by year end, the firm’s director general said on Tuesday. “Our objective is to bring…

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.